EGFR and neoplasm: On the other hand, the 50-year-old patient (P36) had NSCLC with bone metastasis and carried composite EGFR mutations, namely p.E746_A750del/p.L861R, had received 2 months of erlotinib therapy, during which he showed a 63% tumor regression.